Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.

Cholesterol plaque in artery

The possibility of treating patients who cannot tolerate statins has long been eyed as a valuable segment of the cholesterol market, but has been a difficult claim to get past regulators. However, recent developments arguably may help build a market for what has been a hard-to-define population.

The majority of the cholesterol market is well-served by statins, which offer effective LDL lowering now as oral generic drugs....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category